Key to the development of ReveraGen’s lead compound, VBP15, was the recognition that there are sub-properties of glucocorticoids that are associated with either efficacy or side effects.
ReveraGen's expertise in steroid chemistry was used to change the steroid chemistry to optimize for these sub-properties: transactivation (linked to side effects), Learn more >
In the News
Parent Project Muscular Dystrophy and Foundation to Eradicate Duchenne Award $1 Million Grant to ReveraGen BioPharma
Parent Project Muscular Dystrophy (PPMD) and Foundation to Eradicate Duchenne (FED) today announced that they will award ReveraGenBioPharma (ReveraGen) a $1 million grant. The grant will help fund ReveraGen’s VBP15, a combined action drug that addresses multiple levels of the muscle disease Duchenne muscular dystrophy Learn more >
At ReveraGen, we are committed to improving the lives of neuromuscular disease patients.
We are a drug development company engaged in the discovery and development of proprietary therapeutic products for neuromuscular and inflammatory diseases. We are pursuing small molecule drug development for selected indications. ReveraGen’s lead compound, VBP15, is a novel anti-inflammatory currently in development for the chronic treatment of Duchenne muscular dystrophy (DMD). Additional indications and second-generation product candidates are in the pipeline.